Cargando…
Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recogniz...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2001
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138708/ https://www.ncbi.nlm.nih.gov/pubmed/11737893 http://dx.doi.org/10.1186/bcr330 |